Abstract 177P
Background
Stomach cancer (SC) ranks as the 3rd leading cause of death among all cancer-related fatalities in the South Asia (SA) region. The complex interplay of cultural, lifestyle, and demographic factors in SA compounds the challenge to public health posed by the significant burden of stomach cancer.
Methods
Using the Global Burden of Disease framework, this study examined deaths and disability-adjusted life years (DALYs) attributed to SC caused by smoking by age, sex, and year across the 5 countries of the SA region from 1990-2019. Additionally, projections for the number of deaths up to 2040 were derived through regression analysis.
Results
The total count of deaths attributed to SC due to smoking witnessed an increase from 6,948 (95%UI: 4,963-8,890) in 1990 to 9,353 (95%UI: 6,632-12,325) in 2019. Concurrently, DALYs rose from 177,675 (95%UI: 124,165-232,327) in 1990 to 222,290 (95%UI: 149,831-299,787) in 2019. Assessing the annual percentage of change (APC), the Age-Standardized Mortality Rate (ASMR) experienced a decline of 49% from 1990-2019. Among the SA countries, Nepal exhibited the highest APC increase in total deaths at 76%, followed by Bhutan at 73%, India at 40%, Pakistan at 20%, and Bangladesh at 13% from 1990-2019. Conversely, the APC increase in DALYs was greatest in Nepal at 51%, while Bangladesh reported the lowest increase at 3% during the same period. Notably, the age group of 65-69 years recorded the highest number of deaths (1,555), while the age group of 60-64 years experienced the highest DALYs (37,194) in 2019. In terms of gender disparities, males bore a higher burden of stomach cancer attributable to smoking compared to females over the past three decades. The study's projections indicate an estimated 3,952 deaths (95%UI: 2,036-6,347) by the year 2040.
Conclusions
While notable advancements have been made in the management of SC, the burden attributed to smoking continues to rise over the last 3 decades. This accounts for 9.44% of deaths among the overall causes of SC-related fatalities. It emphasizes the importance of comprehensive tobacco control strategies to mitigate this burden, considering the diverse social, economic, and cultural factors unique to the region.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract